Wijkstra 2010.

Study characteristics
Methods	Randomised, double‐blind study
Participants	DSM‐IV‐defined psychotic depression Inpatients
Interventions	7 weeks of treatment with imipramine (plasma levels 200 to 300 μg/L), venlafaxine (375 mg/d), venlafaxine + quetiapine (375 mg/d + 600 mg/d)
Outcomes	Dichotomous data: study author defined (response). Response is ≧ 50% decrease in HAM‐D 17 scores from baseline to study endpoint, and final HAM‐D score ≦ 14. Remission is HAMD ≦ 7 (not predefined)
Notes	No quetiapine arm. Inclusion did not reach planned number (122 i.s.o. 155) Relatively low dropout rate (22/122 = 18%)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	As reported: "randomisation was executed centrally using a computer‐generated randomisation list: randomly permuted blocks of size six"
Allocation concealment (selection bias)	Low risk	As reported: "randomisation was executed centrally"
Blinding (performance bias and detection bias) of participants	Low risk	Study was double‐blind. Blood was collected from each participant (only imipramine blood level was assessed). Treatment guesses were analysed and indicated high preservation of blindness
Blinding (performance bias and detection bias) of personnel	Low risk	Double‐blind study. Blood was collected from each participant (only imipramine blood level was assessed). Treatment guesses were analysed and indicated high preservation of blindness
Blinding (performance bias and detection bias) of outcome assessors	Low risk	As reported: "blindness was checked and high. All dose adjustments were done centrally by an independent psychiatrist"
Incomplete outcome data (attrition bias) All outcomes	Low risk	None
Selective reporting (reporting bias)	Low risk	Protocol available. Generally accepted outcomes have been used
Other bias	Unclear risk	122 participants included i.s.o. with the planned 155 resulting in loss of power Post hoc remission as secondary outcome measure